Novel Dihydropyridine Series Delivers Potent Caspase-1 Antagonists
- A new series of dihydropyridine-derived small molecules is reported as antagonists of caspase-1, a cysteine protease central to inflammasome signaling.
- Caspase-1 activation drives maturation of the pro-inflammatory cytokines IL-1β and IL-18, making it a longstanding target in inflammation and inflammasome-related disease research.
- The dihydropyridine scaffold, more commonly associated with calcium-channel pharmacology, is explored here as a chemotype for caspase-1 antagonism.
- Compound activity was characterized using in vitro fluorescence-based enzymatic assays to gauge caspase-1 antagonism.
- Cell imaging was used alongside the biochemical assays to examine compound behavior and target engagement in a cellular context.
- The study, published in ChemMedChem, presents this dihydropyridine series as a structure-activity starting point for further caspase-1/inflammasome-directed medicinal chemistry.
First reaction: that's a nifedipine scaffold sitting in a caspase-1 SAR table. Bold, slightly nervy move — DHPs are about as pharmacologically 'loaded' as chemotypes get, so before getting excited about any hit here I'd want an L-type calcium-channel counter-screen and a broader Cav/hERG panel run immediately; that vasodilatory liability doesn't vanish just because you've redirected the scaffold at a protease. Caspase-1 itself is a reasonable target — druggable active-site cysteine, real precedent from peptidomimetic inhibitors — but selectivity across the caspase family, not potency, is the real hurdle here. The fluorescence assay plus cell imaging is the right combo methodologically: biochemical IC50s alone can't distinguish real antagonism from aggregation, chelation, or off-target channel hits, so imaging buys an early cellular engagement check before committing to a full selectivity panel.